论文部分内容阅读
目的评价高强度聚焦超声(HIFU)联合内分泌治疗前列腺癌(PCa)的疗效和副作用。方法PCa患者65例,B期12例,C期32例,D期21例,平均PSA为(85.5±79.4)ng/ml;以HIFU联合内分泌治疗,随访PSA和1、3、5年生存率,观察治疗的副作用。结果55例获得12～46个月的随访;术后3个月平均PSA为(53.4±51.3)ng/ml,与术前相比具有显著性差异(P<0.01),患者1、3、5年生存率分别为87.2%、38.2%和23.6%,副作用轻微。结论HIFU联合内分泌治疗前列腺癌能有效地降低PSA,提高患者生存率,具有高度安全性。
Objective To evaluate the efficacy and side effects of high intensity focused ultrasound (HIFU) combined with endocrine in the treatment of prostate cancer (PCa). Methods 65 patients with PCa, 12 patients in stage B, 32 patients in stage C, 21 patients in stage D, the mean PSA was (85.5 ± 79.4) ng / ml. HIFU combined with endocrine therapy was followed up for PSA and 1,3,5 year survival rate , Observe the side effects of treatment. Results 55 cases were followed up for 12 to 46 months. The mean PSA at 3 months after operation was (53.4 ± 51.3) ng / ml, which was significantly different from that before operation (P <0.01) The annual survival rates were 87.2%, 38.2% and 23.6%, respectively, with minor side effects. Conclusion HIFU combined with endocrine treatment of prostate cancer can effectively reduce PSA, improve patient survival rate, with a high degree of safety.